Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 2Virus Diseases 1Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × halofantrine × Clear all
NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00426361 2018-07-20

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

GlaxoSmithKline

Phase 3 Completed
751 enrolled 22 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡